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Case Report
Classical Findings of Infantile Hepatic Hemangiomas
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Abstract
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Introduction
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Hemangiomas are benign vascular tumors that are common during infancy. They are most
commonly noted as superficial bright red lesions on the skin but can also be found deeper
as subcutaneous lesions. Patients with multifocal cutaneous hemangiomas are at risk of
visceral involvement with the liver being most commonly affected. Most hemangiomas can
be monitored clinically as they are self-limiting. Despite this, hepatic hemangiomas can have
serious complications including large arteriovenous shunts leading to cardiac compromise as
well as severe hepatomegaly which can cause abdominal compartment syndrome, impaired
ventilation and renal vein compression.
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Clinical Findings

A six-month-old female, born full term and previously healthy, presented due to worsening
abdominal distention and hepatomegaly. On examination, abdominal distention, hepatomegaly and three superficial hemangiomas on her torso and scalp were appreciated.

Outcome

The patient had an extensive workup which showed an elevated AFP and TSH. An abdominal
ultrasound revealed numerous rounded regions of hypoechogenicity throughout the hepatic
parenchyma. These findings were consistent with diffuse infantile hemangiomas; however, metastasis could not be ruled out with ultrasound alone. An MRI of the abdomen was
obtained which confirmed infantile hemangiomas. The patient’s MRI and lab findings are the
classical findings of infantile hepatic hemangiomas. She had elevated blood pressures during
the hospital course and was subsequently evaluated by cardiology for concern of cardiac
compromise. Treatment with propranolol was initiated and continued upon discharge. A six
month follow-up ultrasound showed significant decrease in size of the hemangiomas.

Conclusion

Hepatic hemangiomas should be monitored closely for serious complications. Although rare,
it is important to identify which patients with multifocal cutaneous hemangiomas should
be worked up for hepatic hemangiomas and their complications. It is recommended that infants younger than 6 months of age with 5 or more cutaneous hemangiomas undergo early
evaluation with abdominal ultrasound.
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Background

Hemangiomas are benign vascular tumors that
are common during infancy. Approximately 5 to
10% of one-year-olds have a superficial hemangioma, with females being more commonly
affected than males at a ratio of 3:1. Hemangiomas are also more common in white, non-Hispanic infants and preterm infants. They are
characterized as clusters of proliferating endo-

thelial cells that demonstrate rapid proliferation and growth for up to 14 months, followed
by a slow regression. This involution phase can
take 3 to 10 years to complete. Hemangiomas
in early infancy occasionally appear as superficial pale white macules with telangiectasia that
progress to bright red, elevated lesions on the
skin. Subcutaneous lesions appear as a mass
with a bluish hue or discoloration to the skin.
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Figure 1. Superficial hemangioma measuring 10 mm on posterior left hip.
Most hemangiomas are monitored clinically as
they are self-limiting; however, there are certain presentations that require further workup
and management. Patients with multifocal cutaneous hemangiomas are at risk of visceral involvement with the liver being most commonly
affected. Hepatic hemangiomas can have
serious complications including large arteriovenous shunts leading to cardiac compromise, as
well as severe hepatomegaly, which can cause
abdominal compartment syndrome, impaired
ventilation and renal vein compression.

Case Presentation

A previously healthy six-month-old biracial
full-term female presented to the emergency
department due to abdominal distention and
hepatomegaly discovered during a routine wellchild check. The patient had a previous history
of abdominal distention, which was attributed
to constipation and gas. This distention had
been unresponsive to formula changes, over
the counter oral simethicone and altered feeding strategies. The child had no other associated symptoms and demonstrated appropriate
weight and developmental milestone progression. Review of systems was negative for
preceding illness, fever, lethargy, poor appetite,
decreased urine output, bloody stools, hematuria, rashes and easy bruising.
On arrival to the emergency room, the patient’s
vital signs comprised of temperature 36.3°C,
pulse 110 bpm, blood pressure 115/69 mmHg,
respiratory rate 32, SpO2 97%, weight 7.145 kg
and height 61.5 cm. Her weight and height were
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in the 27th and 3rd percentile for age, respectively. It was noted that the patient was fussy
and crying while vitals were taken. On physical
examination she was playful, well developed
and in no distress. She had a regular heart rate
and rhythm with no murmurs and equal pulses in all four extremities. Her abdomen was
distended but soft. Hepatomegaly was noted,
as well as an easily reduced umbilical hernia.
She had a 2 mm bright red macule on the right
frontal scalp, a 2 mm bright red macule on the
left chin and a 10 mm bright red papule on the
posterior left hip. (Figure 1) The remainder of
her exam was unremarkable.
The patient had an extensive workup in the
emergency department including complete
blood count, comprehensive metabolic panel,
alpha fetoprotein, human chorionic gonadotropin, lactate dehydrogenase, uric acid and
lactate. Her platelets were slightly elevated at
468,000 per microliter. Alpha fetoprotein was
elevated at 34.9 ng/ml. Comprehensive metabolic panel results showed elevated alanine
transaminase at 43 IU/L. All other labs were
within normal limits. Her chest x-ray, looking
for possible metastasis and/or mediastinal
masses, was normal. An abdominal ultrasound
revealed numerous rounded regions of hypoechogenicity throughout the hepatic parenchyma, the largest measuring 4.63 x 2.98 cm.
(Figure 2) These findings were consistent with
diffuse infantile hemangiomas; however, metastasis could not be ruled out with ultrasound
alone. The patient was admitted to the pediatric hematology/oncology service for further
management.
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Figure 2. Hepatic ultrasound, sagittal view, obtained at admission with a hemangioma measuring
4.63 x 2.98 cm (arrow).
During the hospital course, an abdominal magnetic resonance imaging (MRI) with and without contrast was obtained, illustrating lesions
throughout the hepatic parenchyma consistent
with diffuse infantile hemangiomas (Figure 3,
Figure 4), the largest being 1.6 x 3 x 4.4 cm. At
this time thyroid stimulating hormone and free
thyroxine were collected as hypothyroidism
occasionally occurs with hepatic hemangiomas.
Thyroid stimulating hormone was elevated at
9.39 uIU/ml, as normal range for age is 0.58 to
5.56 uIU/ml. Free thyroxine was within normal
limits. The constellation of the patient’s history,
imaging and laboratory findings was consistent
with infantile hepatic hemangiomas.

The hospital course was complicated by elevated blood pressures. The highest blood
pressure recorded was 134/79 mmHg, which is
in the 99th percentile for age for systolic and
diastolic blood pressures. Manual blood pressures averaged approximately 100s/70s, which
is in the 97th percentile for age for systolic
blood pressure and the 99th percentile for age
for diastolic blood pressure. Pediatric cardiology was consulted over concerns for cardiac
dysfunction. Echocardiography demonstrated
normal anatomy and wall motion, with incidental normal variant trace tricuspid regurgitation
and pulmonary insufficiency. Cardiology recommended starting treatment with close monitoring of blood pressures and blood glucose.

Figure 3. MRI abdomen showing hepatomegaly secondary to innumerable hepatic hemangiomas.
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Figure 4. MRI abdomen showing possible renal compression secondary to hepatomegaly.
Treatment for the infantile hemangiomas
included propranolol 0.5 mg/kg/dose twice
daily. She was monitored for hypoglycemia and
hypotension, which she did not encounter. Her
elevated thyroid stimulating hormone and normal thyroxine were interpreted as compensated hypothyroidism. The patient was discharged
and her parents were instructed to complete
an increasing propranolol dosing regimen with
a target of 1 mg/kg/dose twice daily.
At the patient’s six month follow-up, her
abdominal ultrasound showed a significant
decrease in hepatic hemangiomas, with the
largest being 2.42 cm. (Figure 5) However, her
superficial hemangiomas had not changed
significantly in size. The patient continues to
follow-up with cardiology and her follow-up
echocardiograms are unchanged and show no
signs of cardiac compromise.

Discussion

Infantile hemangiomas are the most common
benign tumors of childhood. Most hemangiomas are self-limiting and can be monitored
without intervention. Rarely, hemangiomas
can be life threatening, so it is imperative for
physicians to know the indications requiring
further investigation. Clinical guidelines recommend that patients younger than six months of
age with five or more cutaneous hemangiomas
be worked up for hepatic hemangiomas, as the
liver is the most commonly effected visceral
organ.1,2 Usually, an abdominal ultrasound is
sufficient for diagnosis.1,2 Diagnostic criteria for
hepatic hemangiomas via ultrasound are the
following: (1) ultrasound showing well demarcated, homogeneous hyperechoic masses, (2)
lesions less than 3 cm and (3) no past history
of cirrhosis or extrahepatic malignancy. In this

Figure 5. Hepatic ultrasound, sagittal view, with a hemangioma measuring 2.42 cm (arrow), obtained 6 months after treatment.
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case, the ultrasound noted hypoechoic masses.
Hypoechogenicity is secondary to the surrounding parenchyma, giving a bright signal. An
MRI with contrast was recommended because
the ultrasound diagnostic criteria was not met.
An MRI with contrast has a 90% sensitivity and
specificity for the diagnosis of intrabdominal
infantile hepatic hemangiomas.3

is repeated at an adjusted dose for the patient’s weight. For this patient, the six month
follow-up ultrasound showed improvement in
the total number and size of the hemangiomas.
This patient was continued on propranolol for
an additional six months by the pediatric cardiology team.

Once hepatic hemangiomas are diagnosed it is
recommended to screen the infant for hypothyroidism.1,4 Hepatic hemangiomas can cause
consumptive hypothyroidism, which was seen
in this case. This is secondary to a thyroid deactivating enzyme, type 3 iodothyronine deiodinase, which is produced in excess during the
proliferative phase of hepatic hemangiomas.
This usually does not require treatment.4,5

Infantile hepatic hemangiomas are fairly
benign but should be monitored closely as
their rapid proliferation can lead to significant
complications. Clinical guidelines recommend
that patients younger than six months of age
with five or more cutaneous hemangiomas be
evaluated for hepatic hemangiomas. A diagnosis is usually made by abdominal ultrasound.
Once confirmed, patients should be screened
for hypothyroidism and treated accordingly.
Most hepatic hemangiomas can be closely
monitored without intervention. Treatment is
indicated based on clinical concern for possible
complications, including cardiac compromise
and abdominal compartment syndrome. The
first line therapy is propranolol 2 mg/kg/dose
twice daily for six months. This case features
excellent imaging and lab results that are consistent with infantile hepatic hemangiomas as
well as significant improvement with appropriate management.

Pharmacologic treatment is recommended for
hepatic hemangiomas based on clinical concern for possible complications. Complications
include large arteriovenous shunts leading to
cardiac compromise as well as severe hepatomegaly leading to abdominal compartment
syndrome, impaired ventilation and renal vein
compression.1,5 This patient’s age and rapidly
progressing abdominal distention were indications for initiating treatment. Infantile hepatic
hemangioma treatment coincides with treatment of other high-risk hemangiomas. The
first line therapy is propranolol, a nonselective
beta-blocker that vaso-constricts blood vessels. This process decreases the expression of
vascular endothelial growth factor leading to
apoptosis. In theory, propranolol inhibits the
proliferation of hemangiomas and prompts
the regression phase.6 Contraindications of
propranolol use are premature infants with
corrected age less than five weeks, history of
bronchospasms or wheezing, conditions affecting blood glucose and cardiac compromise.
Cardiac compromise includes heart failure,
chronic bradycardia, second/third degree heart
block and cardiogenic shock.7 If any of the
above are noted other treatments should be
sought out or propranolol should be initiated
under the guidance of a cardiologist. The initial
propranolol dose is often 0.5 mg/kg/dose twice
daily and advanced by 0.5 mg/kg weekly, as tolerated, to a goal of 2 mg/kg/dose twice daily.
Patients are kept on this dosage for six months
and reevaluated. If hemangiomas reoccur or
further regression is desired, a second course

Conclusion
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